Real-Life International Normalized Ratio Profile in Patients with Non-Valvular Atrial Fibrillation Prescribed Vitamin K Antagonist
Abstract
Coagulation status with vitamin K antagonists (VKAs) needs to be monitored carefully to ensure maximal efficacy with minimal complication rates.
Aim. To study the international normalized ratio (INR) values in patients on VKAs in selected area, find out which patient characteristics that is associated with good INR control and calculation of the time in the therapeutic range (TTR) according to the number of INR/Patient.
Material and methods. A total of 200 patients with non-valvular atrial fibrillation prescribed vitamin K antagonist as anticoagulant were evaluated. They were divided into two groups: group I with TTR≥65% (n=93) and group II with TTR<65% (n=107). Stroke and hemorrhagic risks were calculated by means of the CHA2DS2-VASc score and HAS-BLED score, respectively. Presence of comorbid diseases was assessed by the Charlson index. TTR was calculated using Rosendaal method.
Results. Patients in group I (TTR≥65%) were younger (p<0.001), more often men (p<0.074) with a high level of education (p<0.001), had lower stroke and hemorrhagic risks (mean CHA2DS2-VASc score was 1.0 and HAS-BLED score – 0.0), and also had fewer comorbidities (mean Charlson index was 0.0; p<0.001) compared to patients in group II (TTR<65%). The rate of inadequate control with VKAs (TTR<65) was 52%. Multivariate logistic regression analysis was done to see the significant independent predictors for a good INR control i.e. TTR≥65%. It was found that high level of education compared to lower levels is the only significant independent predictor for obtaining good INR control (odds ratio=133, 95% confidence interval 34.24-514.44, p<0.001).
Conclusion. It was found that high level of education compared to lower levels is the only significant independent predictor for obtaining good INR control.
About the Authors
S. I. Farag
Benha University
Egypt
Egypt
Shereen Ibrahim Farag – MD, Cardiovascular Medicine Department, Faculty of Medicine
Fareed Nada Street, Benha, Qalubiya Governorate, 13511
O. S. Arafa
Benha University
Egypt
Egypt
Osama Sanad Arafa – MD, Cardiovascular Medicine Department, Faculty of Medicine
Fareed Nada Street, Benha, Qalubiya Governorate, 13511
A.A. E. Hassan
Benha University
Egypt
Egypt
Amal Abou Elfadl Hassan – MD, Medical Biochemistry and Molecular Biology Department, Faculty of Medicine
Fareed Nada Street, Benha, Qalubiya Governorate, 13511
H. M. Mashhour
Benha University
Egypt
Egypt
Haidy Magdy Mashhour – MBBCH, Cardiovascular Medicine Department, Faculty of Medicine
Fareed Nada Street, Benha, Qalubiya Governorate, 13511
A. M. Bendary
Benha University
Egypt
Egypt
Ahmed Mahmoud Bendary – MD, Cardiovascular Medicine Department, Faculty of Medicine
Fareed Nada Street, Benha, Qalubiya Governorate, 13511
References
1. Mearns E.S., White C.M., Kohn C.G., et al. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J. 2014;12(1):14. DOI:10.1186/1477-9560-12-14.
2. Baker W.L., Cios D.A., Sander S.D., et al. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15(3):244-52. DOI:10.18553/jmcp.2009.15.3.244.
3. Anderson J.L., Horne B.D., Stevens S.M., et al. Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation. Circulation. 2007;116(22):2563-70. DOI:10.1161/CIRCULATIONAHA.107.737312.
4. Rosendaal F.R., Cannegieter S.C., van der Meer F.J., et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236-9.
5. Connolly S.J., Pogue J., Eikelboom J., et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Clin Ther. 2008;118:2029-37. DOI:10.1161/CIRCULATIONAHA.107.750000.
6. Vicente B.G., Manuel A., Josemoreno A., et al. quality of anticoagulation with vitamin K antagonists. Clin Cardiol. 2015;38(6):357-64. DOI:10.1002/clc.22397.
7. Cott´e F.E., Benhaddi H., Duprat-Lomon I., et al. Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries. Clin Ther. 2014;36:1160-8. DOI:10.1016/j.clinthera.2014.07.016.
8. Le Heuzey J.Y., Ammentorp B., Darius H., et al. Differences among Western European countries in anticoagulation management of atrial fibrillation: data from the PREFE R IN AF registry. Thromb Haemost. 2014;111:833-41. DOI:10.1160/TH13-12-1007.
9. Li X., Sun S., Wang Q., et al. Assessment of patients’ warfarin knowledge and anticoagulation control at a joint physician-and pharmacist-managed clinic in China. Patient Prefer Adherence. 2018;12:783. DOI:10.2147/PPA.S156734.
10. Tang E.O.Y.L., Lai C.S.M., Lee K.K.C., et al. Relationship between patients’ warfarin knowledge and anticoagulation control. Ann Pharmacother. 2003;37(1):34-9. DOI:10.1345/aph.1A198.
11. Platt A.B., Localio A.R., Brendinger A.M., et al. Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmacoepidemiology and Drug Safety. 2008;17:853-60. DOI:10.1002/pds.1556.
12. Baker W.L., Cios D.A., Sander S.D., et al. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15:244-52. DOI:10.18553/jmcp.2009.15.3.244.
13. Agnes R., Olivier H., Anne-Sophie B., et al. Comorbidities against Quality Control of VKA Therapy in Non-Valvular Atrial Fibrillation. Clin Res Cardiol. 2015;10(5):e0128867. DOI:10.1371/journal.pone.0119043.
14. Skeppholm M., Friberg L. Adherence to warfarin treatment among patients with atrial fibrillation. Clin Res Cardiol. 2014;103(12):998-1005. DOI:10.1007/s00392-014-0742-y
Review
For citations:
Farag S.I., Arafa O.S., Hassan A.E., Mashhour H.M., Bendary A.M. Real-Life International Normalized Ratio Profile in Patients with Non-Valvular Atrial Fibrillation Prescribed Vitamin K Antagonist. Rational Pharmacotherapy in Cardiology. 2020;16(4):522-527. https://doi.org/10.20996/1819-6446-2020-08-14
Views: 387
Email this article 